Filter by: patients
Home > Community Treatment Reports and Side Effects > Alemtuzumab Treatment Report
What is Alemtuzumab?

Alemtuzmab, marketed as Campath, is indicated as a single agent for the treatment of B-cell chronic lymphocytic leukemia (B-CLL). It has been used as an experimental drug treatment for multiple sclerosis.

Reported Purpose & Efficacy

Reasons and Efficacy
Purpose # of patients
# of patients with evaluations Efficacy
Major
Moderate
Slight
None
Can’t tell
MS (Multiple Sclerosis) 22 11 Efficacy_major Efficacy_moderate Efficacy_slight Efficacy_none Efficacy_cant_tell
experimental 4 1 Efficacy_major
Other 2 1 Efficacy_major
Kidney Transplant 1 0
Support immune health 1 1 Efficacy_major

See all 17 patients currently taking Alemtuzumab

Mouse over the table for more information

Reported Side Effects

Side effects as an overall problem

Severe
 0
Moderate
 6
Mild
 3
None
 4

Commonly reported side effects, conditions, and hospitalizations associated with Alemtuzumab

Chills/fever 4
Generalized weakness (asthenia) 3
Fatigue 3
Headaches 3
Allergic reaction 3
Infection 2
See all 22 reported side effects ▼ See top 6 reported side effects ▲

Reported Dosages

Frequently reported dosages based on patients currently taking Alemtuzumab. See all 13 dosages ►

  10 mg yearly 12 other yearly 30 mg yearly 50 mg yearly 125 mg yearly 150 mg yearly 10 mg daily 12 mg daily 30 mg one time 50 mg one time
  4 Number of Patients: 4 1 Number of Patients: 1 3 Number of Patients: 3 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1 1 Number of Patients: 1  

Reported Stop Reasons

Why Patients Stopped Taking Alemtuzumab (multiple reasons could be selected)
Reason # Patients Percentage of patients
Course of treatment ended 11   Course of treatment ended: 73%
Other 2   Other: 13%
Not indicated 2   Not indicated: 13%
Did not seem to work 1   Did not seem to work: 7%

See all 15 patients who’ve stopped taking Alemtuzumab

Reported Duration See details about how long patients take this treatment ▼

Currently Taking Alemtuzumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Stopped Taking Alemtuzumab

A bar graph

0-1 month 1-3 months 3-6 months 6 months-1year 1-2 years 2 years or more
0
0
0

Reported Adherence, Burden & Cost See details from patient evaluations ▼

Adherence

Taking treatment as prescribed

Adherence of Alemtuzumab

Always
 12 92%
Usually
 0 0%
Sometimes
 1 8%
Never
 0 0%

Burden

Difficulty being on treatment

Burden of Alemtuzumab

Very
 0 0%
Somewhat
 4 31%
A little
 2 15%
Not at all
 7 54%

Cost

Paid out of pocket

Cost of Alemtuzumab

$200+
 0 0%
$100-199
 0 0%
$50-99
 0 0%
$25-49
 0 0%
< $25
 8 100%

See more information, including instructions, precautions, side effects, and interactions.

Report created on May 28, 2012.